Press Release

  • Reset
A Note From Our Chair – Innovators Summit 2023
Just another magic Monday as I am still buzzing from the evidence, insights and perspectives from our 2023 Fall Innovators Summit. Here are some more summaries of the 100+ speakers from NYC’s largest Digital Health Summit, including:
HITLAB Announces Winners of Fall 2023 Breakthrough Alliance Challenge
Today HITLAB announced the winners of its Fall 2023 Breakthrough Alliance (BTA) Innovator’s challenge. The BTA is a digital health consortium founded in partnership with New York City Economic Development Corporation and was created to accelerate the optimal adoption of digital health innovations through shared evidence, communication, and perspectives to improve health outcomes, access and care delivery.
HelixVM™: Randomized Clinical Trial Demonstrates Marketplace’s Ability to Advance Healthcare Access with Improved Provider Capacity
New York, NY. (November 29, 2023) – HelixVM™, a virtual healthcare marketplace, showcases its ability to significantly increase physician capacity, revolutionizing the way healthcare is delivered. The pioneering marketplace platform demonstrated the capability to streamline patient-doctor interactions, leading to efficient care with providers in the study seeing clear evidence of HelixVM improving access to healthcare.
HITLAB Announces Finalists for Fall 2023 Breakthrough Alliance Challenge
Today HITLAB announced the five finalists selected for the Fall 2023 Breakthrough Alliance (BTA) Innovator’s challenge. The BTA is a digital health consortium which was created to accelerate a greater number of innovations to improve health outcomes and care delivery through verified emerging technologies.
Clinical Trial Adherence Intelligence
With 90% of clinical trials failing¹ to meet FDAapproval, researchers, regulators, sponsorsand other stakeholders have worked tirelesslyto identify causes of such high failure rates;many reasons are cited, including failure tomeet statistical endpoints, insufficient patientenrollment, safety issues and failure to meetFDA protocols.
Curio Digital Therapeutics: Pivotal Trial for Postpartum Depression Digital Therapeutic Meets Efficacy Endpoints
Curio Digital Therapeutics, Inc. (“Curio”), today announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial. SuMMER (NCT05958095), a study executed by HITLAB, a renowned healthcare innovation and research organization, is a randomized clinical trial of MamaLift Plus, a digital therapeutic for women experiencing perinatal mood disturbances.